FTRE — Fortrea Holdings Inc.

Summary of Fortrea (FTRE) Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $678.2 million, a 4.5% decrease year-over-year primarily due to lower pass-through costs.
• Adjusted EBITDA: $58.7 million, up from $54.9 million in the prior year, driven by cost optimization and operational efficiencies.
• Net Loss: $13.2 million, significantly improved from a net loss of $374.9 million in the prior year, which included a goodwill impairment charge.
• Adjusted Net Income: $22.7 million, compared to $17.6 million in the previous year.
• Book-to-Bill Ratio: 1.06x for the quarter, with a trailing 12-month ratio of 1.12x, indicating sustained commercial momentum.
• Backlog: $7.8 billion, with cancellations in line with historical trends.
• Operating Cash Flow: Positive $28.9 million, up from $21.8 million year-over-year.
• Free Cash Flow: Positive $19.9 million, compared to $14.3 million in Q2 2025.

2. Strategic Updates and Business Highlights

• Fortrea's commercial strategy focuses on "3 Rs": reach, relevance, and repeat, leading to $720.4 million in net new business, primarily in biotech.
• The Clinical Pharmacology Services (CPS) segment showed strong performance, contributing to revenue growth.
• The company is investing in AI and technology integration through its Fortrea Intelligent Technology (FIT) initiative, aiming to enhance operational efficiency and client outcomes.
• Leadership transition occurred with Jason Madlock unable to serve as CFO due to a legal matter; David Smith is acting as interim CFO.

3. Forward Guidance and Outlook

• Full-year 2026 revenue guidance increased to $2.62 billion - $2.69 billion, with adjusted EBITDA guidance raised to $205 million - $220 million.
• Expectations for continued positive free cash flow for the remainder of 2026.
• The company remains focused on sustainable growth, margin expansion, and disciplined capital allocation.

4. Bad News, Challenges, or Points of Concern

• Revenue decline year-over-year due to lower pass-through costs and ongoing headwinds in the Functional Service Provider (FSP) segment.
• The CFO transition could pose risks if not managed effectively.
• Competitive pressures remain high in the CRO industry, with the need for continuous improvement in commercial execution and operational performance.

5. Notable Q&A Insights

• Management acknowledged the ongoing FSP drag but highlighted improvements in CPS and a better study mix contributing to margins.
• There was discussion on the competitive landscape, indicating a return to rational pricing behaviors in the industry.
• AI capabilities are becoming a differentiator in RFP processes, but meaningful commercial impacts from AI adoption are expected to take time.
• The company is seeing improved engagement from both pharma and biotech clients, with a focus on diversifying its client base and project types.

Overall, Fortrea reported a solid quarter with improved financial metrics and strategic initiatives aimed at enhancing commercial and operational performance, despite facing some challenges in revenue and competitive pressures.